Below you will find a current list of Hemophilia A products along with their death and adverse reactions data.
By looking at this data, emicizumab (Hemlibra) has the most negative data in such a short period of time since FDA approval.
BRAND
DEATHS
ADVERSE REACTIONS
FDA APPROVAL
HEMLIBRA
54
700
OCTOBER 2018
ADVATE
133
2,572
DECEMBER 2011
ADYNOVATE
15
280
NOVEMBER 2015
AFSTYLA
2
46
MAY 2016
ELOCTATE
23
488
JUNE 2014
ESPEROCT
1
6
FEBRUARY 2019
JIVI
1
50
AUGUST 2018
KOGENATE
46
1,316
MARCH 2009
KOVALTRY
15
197
MARCH 2016
NOVOEIGHT
15
89
OCTOBER 2013
NUWIQ
2
21
SEPTEMBER 2015
RECOMBINATE
27
481
UNKNOWN
XYNTHA
28
355
FEBRUARY 2008